Merck Sees FDA OK for Six-Week Keytruda Dosing in Six Indications
July 09 2019 - 7:27AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Tuesday said the U.S. Food and Drug
Administration accepted for review applications to include an
every-six-weeks dosing schedule for its cancer drug Keytruda in six
indications.
The Kenilworth, N.J., drug maker said it filed the six
supplemental biologics license applications to update the dosing
frequency for Keytruda in melanoma, classical Hodgkin lymphoma,
primary mediastinal large B-cell lymphoma, gastric cancer,
hepatocellular carcinoma and Merkel cell carcinoma.
Merck said the agency has set a target action date of Feb. 18,
2020.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, is currently approved for dosing every three
weeks.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 09, 2019 07:12 ET (11:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
